ClinicalTrials.gg
CompletedNCT02348723Updated Jan 29, 2018Results posted

Uninterrupted Dabigatran Etexilate in Comparison to Uninterrupted Warfarin in Pulmonary Vein Ablation (RE-CIRCUIT)

A Phase 4 interventional study of Warfarin and Dabigatran Etexilate 150mg in Atrial Fibrillation, sponsored by Boehringer Ingelheim. Completed at 87 sites in 11 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-01-29.

Sponsored by Boehringer Ingelheim · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
678
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 35 studies testing dabigatran in Atrial Fibrillation — none open to participants now, 1 under way, none of them phase 3. Dabigatran · Atrial Fibrillation.

Enrollment
6th of 35
678 · median 174
Started
2015
with 3 others
Phase 4
22 of 35
none open now
Registered
20th of 35
by date
Lead sponsor
7 of 35
Boehringer Ingelheim

Among the 35 studies testing dabigatran in Atrial Fibrillation, this one is the 6th largest by enrollment, is one of 4 that started in 2015, is one of 22 in phase 4, and was the 20th registered.

Atrial Fibrillation

4,011 studies on the registry are indexed under Atrial Fibrillation; 961 are open to participants now.

Browse Atrial Fibrillation studies →

Open to participants now

None of the 35 studies testing dabigatran in Atrial Fibrillation is open now. The open studies under Atrial Fibrillation, anywhere →

About dabigatran

Dabigatran: first FDA approval 2010 (PRADAXA), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 611 Atrial Fibrillation studies recruiting now, 407 (67%) set no upper age limit and 43 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 35 studies testing dabigatran in Atrial Fibrillation as a file.
02

Study summary

The primary objective of this trial is to assess the safety of an uninterrupted dabigatran etexilate periprocedural anticoagulant regimen compared to an uninterrupted warfarin regimen in Non-Valvular Atrial Fibrillation (NVAF) patients undergoing Atrial Fibrillation (AF) ablation in a PROBE (Prospective, randomized, open label, blinded end point) active controlled study.

Secondary objectives are to assess additional safety endpoints and efficacy in this clinical setting.

It is not intended to assess confirmatory hypothesis, this is an exploratory study.

03

Conditions studied

  • Atrial Fibrillation

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female patients aged >= 18 years.
  • Patients eligible for treatment with dabigatran etexilate 150 mg b.i.d. according to local label.
  • Treatment naïve patients or patients on oral anticoagulant treatment with a Vitamin K Antagonist (VKA), dabigatran etexilate, rivaroxaban, apixaban or edoxaban.
  • Patient with paroxysmal or persistent NVAF with a planned catheter ablation for AF unless it is performed an ablation technique.
  • AF must have been documented at least once either by , Holter monitoring, loop recorder, telemetry, trans-telephonic monitoring, pacemaker or cardiac defibrillator read outs within 24 months prior to screening (Visit 1).
  • The patient must be able to give in accordance with International Conference on Harmonisation (ICH) Good Clinical Practice (GCP) guidelines and local legislation and/or regulations.

Exclusion criteria

Exclusion criteria:

  • Patients with permanent AF.
  • Patients with AF felt to be secondary to an obvious reversible cause such as, but not limited to, an acute myocardial infarction, pulmonary embolism, recent surgery, pericarditis or thyrotoxicosis.
  • Patients with Left Atrium (LA) size >= 60 mm
  • Patients with to systemic anticoagulation with heparin, warfarin or dabigatran etexilate
  • Patients with a known allergy to warfarin tablets and it or to dabigatran etexilate or its excipients
  • Mechanical or biological heart valve prosthesis
  • Severe renal impairment (estimated (CrCl) calculated by Cockcroft-Gault equation) \<30mL/min at screening
  • Stroke within 1 month prior to screening visit
  • Major surgery per investigator judgement within the previous month prior to screening.
  • Patient has received an organ transplant or is on a waiting list for an organ transplant
  • History of intracranial haemorrhage, intraocular, spinal, retroperitoneal or non-traumatic intra-articular bleeding
  • Gastrointestinal haemorrhage within one month prior to screening, unless, in the opinion of the investigator, the cause has been permanently eliminated (e.g. by surgery).
  • Major bleeding episode (ISTH definition) one month prior to the screening visit.
  • Haemorrhagic disorder or bleeding diathesis (e.g. von Willebrand disease, haemophilia A or B or other hereditary bleeding disorder, history of spontaneous intra-articular bleeding, history of prolonged bleeding after surgery/intervention)
  • Anaemia ( \<10g/dL) or thrombocytopenia including heparin-induced thrombocytopenia ( count \<100 x 10\^9/L) at screening
  • Recent or radiation therapy (\<=6 months prior to screening) unless, in the opinion of the Investigator, the estimated is greater than 36 months
  • Active liver disease as indicated by at least one of the following:

    -- Prior and persistent or Aspartate transaminase or alkaline phosphatase >3x and/or -- Known active and/or -- Known active and/or -- Known active hepatitis A

  • Need for continued treatment with systemic ketoconazole, itraconazole, posaconazole, cyclosporine, tacrolimus, dronedarone, rifampicin, phenytoin, carbamazepine, St. John's Wort or any cytotoxic/myelosuppressive therapy.
  • Pre-menopausal (last menstruation \<=1 year prior to screening) who:

    • Are pregnant or breast-feeding or plan to become pregnant during study or
    • Are not surgically sterile or
    • Are of child bearing potential and not practising two acceptable method of , or do not plan to continue practising an acceptable method of birth control throughout the trial
  • Patients who have participated in another trial with an drug or device within the past 30 days preceding the screening visit or are participating in another trial (patients participating in an observational study only will not be excluded)
  • Patients not willing or able to comply with the protocol requirements or considered unreliable by the Investigator concerning the requirements for follow-up during the study and/or compliance with study drug administration, who have a life expectancy less than the expected duration of the trial due to concomitant disease and/or subjects who are institutionalised due to official or court orders and/or vulnerable subjects who are dependent on the Sponsor or the Investigator or the site, or patients who have any condition which in the opinion of the Investigator, would not allow safe participation in the study (e.g. drug addiction, alcohol abuse).
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
678 participants (actual)

Study arms

  • Experimental
    Dabigatran Etexilate 150mg

    Patients receiving Dabigatran Etexilate 150mg twice daily dosing (BID)

    Drug: Dabigatran Etexilate 150mg

  • Active comparator
    Warfarin

    Patients receiving Warfarin to keep International Normalized Ratio (INR) between 2.0 - 3.0

    Drug: Warfarin

Interventions

  • Patients receiving Warfarin to keep International Normalized Ratio (INR)between 2.0 - 3.0

  • Patients receiving Dabigatran Etexilate 150mg twice daily dosing (BID)

06

What researchers measure

Primary outcomes

  1. Incidence of Major Bleeding Events (MBEs), as Defined by the International Society on Thrombosis and Haemostasis (ISTH)

    Major bleeds were defined according to the ISTH definition of a major bleed, as follows * Symptomatic bleeding in a critical area or organ, such as intracranial, intraspinal, intraocular, retroperitoneal, intra-articular or pericardial, or intramuscular with compartment syndrome and/or * Bleeding associated with a reduction in haemoglobin of at least 2 g/dL (1.24 mmol/L), or leading to transfusion of 2 or more units of blood or packed cells. and/or * Fatal bleed These are based on adjudicated data (blinded evaluation) Point estimates for the incidence of ISTH MBEs and their 2-sided 95% confidence intervals (CI), based on the normal approximation of independent binomial distribution without stratification, are presented.

    Time frame: during and up to 2 months post-ablation

Secondary outcomes

  1. Incidence of the Composite of Stroke, Systemic Embolism, or Transient Ischemic Attack (TIA)

    Stroke was defined as an acute episode of focal or global neurological dysfunction caused by brain, spinal cord, or retinal vascular injury as a result of haemorrhage or infarction. Systemic embolism was defined as an acute vascular occlusion of the extremities or any organ (kidneys, mesenteric arteries, spleen, retina or grafts) and was to be documented by angiography, surgery, scintigraphy or autopsy. Transient ischemic attack was defined as a transient episode of focal neurological dysfunction caused by brain, spinal cord, or retinal ischemia, without acute infarction. These are based on adjudicated data (blinded evaluation). Percentage of patients with composite of stroke, systemic embolism, or transient ischemic attack (TIA) is presented

    Time frame: during and up to 2 months post-ablation

  2. Incidence of Minor Bleeding Events

    Minor bleeds were clinical bleeds that did not fulfil the criteria for major bleeds. Percentage of patients with Minor bleeding events are presented. These are based on adjudicated data (blinded evaluation)

    Time frame: during and up to 2 months post-ablation

  3. Incidence of ISTH MBE, Stroke, Systemic Embolism, or TIA (Composite Endpoint Combining Safety and Efficacy

    Percentage of patients with ISTH MBE, stroke, systemic embolism, or TIA (composite endpoint combining safety and efficacy) are presented. These are based on adjudicated data (blinded evaluation)

    Time frame: during and up to 2 months post-ablation

07

Results

Posted Nov 14, 2017

Participant flow

Participant flow — Overall Study
MilestoneDabigatran Etexilate 150 mgWarfarin
Started338338
Completed310312
Not completed2826
Withdrew: No ablation2120
Withdrew: Non-compliant with protocol10
Withdrew: Lost to follow-up11
Withdrew: Consent withdrawn13
Withdrew: Reason other than specified11
Withdrew: Adverse event31

Outcome measures

PrimaryIncidence of Major Bleeding Events (MBEs), as Defined by the International Society on Thrombosis and Haemostasis (ISTH)

Major bleeds were defined according to the ISTH definition of a major bleed, as follows * Symptomatic bleeding in a critical area or organ, such as intracranial, intraspinal, intraocular, retroperitoneal, intra-articular or pericardial, or intramuscular with compartment syndrome and/or * Bleeding associated with a reduction in haemoglobin of at least 2 g/dL (1.24 mmol/L), or leading to transfusion of 2 or more units of blood or packed cells. and/or * Fatal bleed These are based on adjudicated data (blinded evaluation) Point estimates for the incidence of ISTH MBEs and their 2-sided 95% confidence intervals (CI), based on the normal approximation of independent binomial distribution without stratification, are presented.

Time frame:
during and up to 2 months post-ablation
Reported as:
Number · percentage of participants
Incidence of Major Bleeding Events (MBEs), as Defined by the International Society on Thrombosis and Haemostasis (ISTH)
percentage of participantsDabigatran Etexilate 150 mgWarfarin
Incidence of Major Bleeding Events (MBEs), as Defined by the International Society on Thrombosis and Haemostasis (ISTH)1.6 (0.2 to 2.9)6.9 (4.1 to 9.7)
Statistical analysis
  • Dabigatran Etexilate 150 mg vs Warfarin · Chi-squared · p = 0.0009 · Risk difference (rd) %: -5.3 · 95% CI -8.4 to -2.2
SecondaryIncidence of the Composite of Stroke, Systemic Embolism, or Transient Ischemic Attack (TIA)

Stroke was defined as an acute episode of focal or global neurological dysfunction caused by brain, spinal cord, or retinal vascular injury as a result of haemorrhage or infarction. Systemic embolism was defined as an acute vascular occlusion of the extremities or any organ (kidneys, mesenteric arteries, spleen, retina or grafts) and was to be documented by angiography, surgery, scintigraphy or autopsy. Transient ischemic attack was defined as a transient episode of focal neurological dysfunction caused by brain, spinal cord, or retinal ischemia, without acute infarction. These are based on adjudicated data (blinded evaluation). Percentage of patients with composite of stroke, systemic embolism, or transient ischemic attack (TIA) is presented

Time frame:
during and up to 2 months post-ablation
Reported as:
Number · percentage of participants
Incidence of the Composite of Stroke, Systemic Embolism, or Transient Ischemic Attack (TIA)
percentage of participantsDabigatran Etexilate 150 mgWarfarin
Incidence of the Composite of Stroke, Systemic Embolism, or Transient Ischemic Attack (TIA)0.00.3
SecondaryIncidence of Minor Bleeding Events

Minor bleeds were clinical bleeds that did not fulfil the criteria for major bleeds. Percentage of patients with Minor bleeding events are presented. These are based on adjudicated data (blinded evaluation)

Time frame:
during and up to 2 months post-ablation
Reported as:
Number · percentage of participants
Incidence of Minor Bleeding Events
percentage of participantsDabigatran Etexilate 150 mgWarfarin
Incidence of Minor Bleeding Events18.617.0
SecondaryIncidence of ISTH MBE, Stroke, Systemic Embolism, or TIA (Composite Endpoint Combining Safety and Efficacy

Percentage of patients with ISTH MBE, stroke, systemic embolism, or TIA (composite endpoint combining safety and efficacy) are presented. These are based on adjudicated data (blinded evaluation)

Time frame:
during and up to 2 months post-ablation
Reported as:
Number · percentage of participants
Incidence of ISTH MBE, Stroke, Systemic Embolism, or TIA (Composite Endpoint Combining Safety and Efficacy
percentage of participantsDabigatran Etexilate 150 mgWarfarin
Incidence of ISTH MBE, Stroke, Systemic Embolism, or TIA (Composite Endpoint Combining Safety and Efficacy1.67.2

Adverse events

Collected over All Adverse Events (AEs) which occurred after the first dose of trial medication up to 6 days after the last dose of trial medication; up to 225 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Dabigatran Etexilate 150 mg—63/338 (18.6%)68/338 (20.1%)
Warfarin—75/338 (22.2%)65/338 (19.2%)
Most frequent serious events
Showing 10 of 93
Most frequent serious events
EventDabigatran Etexilate 150 mgWarfarin
Atrial flutterCardiac disorders20/33819/338
Atrial fibrillationCardiac disorders6/33813/338
HaematomaVascular disorders0/3386/338
Cardiac tamponadeCardiac disorders1/3384/338
Vascular pseudoaneurysmInjury, poisoning and procedural complications0/3384/338
Cardiac failure congestiveCardiac disorders3/3382/338
Chest painGeneral disorders1/3383/338
Pulmonary oedemaRespiratory, thoracic and mediastinal disorders3/3381/338
Atrial tachycardiaCardiac disorders2/3381/338
Atrial thrombosisCardiac disorders2/3381/338
Most frequent other events
Most frequent other events
EventDabigatran Etexilate 150 mgWarfarin
Atrial fibrillationCardiac disorders40/33838/338
PalpitationsCardiac disorders16/33819/338
Back painMusculoskeletal and connective tissue disorders18/33814/338

Baseline characteristics

Treated set (TS): The treated set (TS) included all patients who were randomised and subsequently treated with at least 1 tablet/capsule.

Age, Continuous
Age, Continuous(years)Dabigatran Etexilate 150 mgWarfarinTotal
Mean59.2 ± 10.3359.4 ± 10.2959.3 ± 10.30
Sex: Female, Male
Sex: Female, Male(Participants)Dabigatran Etexilate 150 mgWarfarinTotal
Female9381174
Male245257502
08

Study locations

87 sites
  • Arkansas Cardiology, PA
    Little Rock, Arkansas 72205, United States
  • Mission Cardiovascular Research Institute
    Fremont, California 94538, United States
  • University of California
    Sacramento, California 95817, United States
  • Mercy Medical Group, a service of Dignity Health Medical Foundation
    Sacramento, California 95819, United States
  • University of California
    San Francisco, California 94143, United States
  • Southwest Florida Research, LLC
    Naples, Florida 34102, United States
  • University of South Florida
    Tampa, Florida 33606, United States
  • Elkhart General Healthcare System
    Elkhart, Indiana 46514, United States
  • Tulane University Hospital and Clinic
    New Orleans, Louisiana 70112, United States
  • Johns Hopkins Hospital
    Baltimore, Maryland 21287, United States
  • St. Louis Heart and Vascular, P.C.
    Saint Louis, Missouri 63136, United States
  • New York Methodist Hospital
    Brooklyn, New York 11215, United States
  • University at Buffalo, The State University of New York
    Buffalo, New York 14203, United States
  • Staten Island University Hospital
    Staten Island, New York 10305, United States
  • University of Oklahoma
    Oklahoma City, Oklahoma 73104-5068, United States
  • Penn State Milton S. Hershey Medical Center
    Hershey, Pennsylvania 17033, United States
  • University of Tennessee Methodist Physicians
    Memphis, Tennessee 38104, United States
  • North Texas Heart Center
    Dallas, Texas 75231, United States
  • St Luke's Health Baylor College of Medicine Med Center
    Houston, Texas 77030, United States
  • University of Utah Health Sciences Center
    Salt Lake City, Utah 84132, United States
  • Providence Regional Medical Center
    Everett, Washington 98201, United States
  • Bonheiden - HOSP Imelda
    Bonheiden, 2820, Belgium
  • Brussels - UNIV UZ Brussel
    Brussel, 1090, Belgium
  • UNIV UZ Gent
    Gent, 9000, Belgium
  • Centre Hospitalier Universitaire de Liège
    Liège, 4000, Belgium
  • Antwerpen - HOSP ZNA Middelheim - Pneumo
    Middelheim, 2020, Belgium
  • Brussels - HOSP Europe (Ste-Elisabeth)
    Ukkel, 1180, Belgium
  • Royal Alexandra Hospital
    Edmonton, Alberta T5H 3V9, Canada
  • Victoria Cardiac Arrhythmia Trials Inc.
    Victoria, British Columbia V8T 1Z4, Canada
  • Kingston General Hospital
    Kingston, Ontario K7L 2V7, Canada
  • Southlake Regional Health Centre
    Newmarket, Ontario L3Y 2P9, Canada
  • CHUS Fleurimont
    Sherbrooke, Quebec J1H 5N4, Canada
  • IUCPQ (Laval University)
    Quebec, G1V 4G5, Canada
  • HOP Nord Michallon
    La Tronche, 38700, France
  • HOP Timone
    Marseille, 13005, France
  • CLI Nouvelles Cliniques Nantaises,Cardio,Nantes Cedex 2
    Nantes, 44000, France
  • HOP Salpêtrière, Cardio, Paris
    Paris cedex 13, 75013, France
  • HOP Européen G. Pompidou
    Paris, 75015, France
  • HOP Haut-Lévêque
    Pessac, 33604, France
  • HOP CHU Nancy Brabois, Cardiologie
    Vandoeuvre les Nancy, 54511, France
  • Vivantes Netzwerk für Gesundheit GmbH
    Berlin, 10967, Germany
  • Universitätsmedizin Göttingen, Georg-August-Universität
    Göttingen, 37075, Germany
  • Universitätsklinikum Hamburg-Eppendorf
    Hamburg, 20246, Germany
  • Universitätsklinikum Schleswig-Holstein, Campus Kiel
    Kiel, 24105, Germany
  • Universitätsklinikum Köln (AöR)
    Köln, 50937, Germany
  • Universitätsklinikum Regensburg
    Regensburg, 93053, Germany
  • Universitätsklinikum Ulm
    Ulm, 89081, Germany
  • Ospedale Generale Regionale "Miulli"
    Acquaviva Delle Fonti (BA), 70021, Italy
  • A.S.O.S. Croce e Carle
    Cuneo, 12100, Italy
  • Osp.dell'Angelo
    Mestre-Venezia, 30174, Italy
  • Fondazione Centro San Raffaele del Monte Tabor
    Milano, 20132, Italy
  • Centro Cardiologico Monzino-IRCCS
    Milano, 20138, Italy
  • Policlinico Casilino U.O. Cardiologia
    Roma, 00169, Italy
  • Anjo-kosei Hospital
    Aichi, Anjo, 446-8602, Japan
  • Nagoya City East Medical Center
    Aichi, Nagoya, 464-8547, Japan
  • Nagoya University Hospital
    Aichi, Nagoya, 466-8560, Japan
  • Japanese Red Cross Nagoya Daini Hospital
    Aichi, Nagoya, 466-8650, Japan
  • Hirosaki University Hospital
    Aomori, Hirosaki, 036-8563, Japan
  • New Tokyo Heart Clinic
    Chiba, Matsudo, 271-0077, Japan
  • Shonan Kamakura General Hospital
    Kanagawa, Kamakura, 247-8533, Japan
  • Sakurabashi Watanabe Hospital
    Osaka, Osaka, 530-0001, Japan
  • Nippon Medical School Hospital
    Tokyo, Bunkyo-Ku, 113-8603, Japan
  • Tokyo Medical University Hachioji Medical Center
    Tokyo, Hachioji, 193-0998, Japan
  • VU Medisch Centrum
    Amsterdam, 1081 HV, Netherlands
  • Onze Lieve Vrouwe Gasthuis
    Amsterdam, 1091AC, Netherlands
  • Catharina Ziekenhuis
    Eindhoven, 5623 EJ, Netherlands
  • Medisch Centrum Leeuwarden
    Leeuwarden, 8934 AD, Netherlands
  • Radboud Universitair Medisch Centrum
    Nijmegen, 6525 GA, Netherlands
  • Heart&Vessels Diseases,Cardiol&Cardiovas.SurgeryDep,Kamerovo
    Kemerovo, 650002, Russian Federation
  • Instit.of Surgery na Vishnevskiy,Treatm.of comp.arrhythm.dep
    Moscow, 117997, Russian Federation
  • City Pokrovskiy Hospital, Cardiology Dept., Saint Petersburg
    Saint Petersburg, 199 106, Russian Federation
  • North-Westrn Fed.med.res.cntr,Almazov Interven.arrhythmo.dep
    St. Petersburg, 197341, Russian Federation
  • Tyumen Cardiology Center, Dept.of Cardiac Arrhythmia
    Tyumen, 625026, Russian Federation
  • Yaroslavl Regional Clin. Hospital, Dept. Endocrinology
    Yaroslavl, 150062, Russian Federation
  • Hospital Clínic de Barcelona
    Barcelona, 08036, Spain
  • Hospital La Paz
    Madrid, 28046, Spain
  • Hospital Virgen del Rocío
    Sevilla, 41013, Spain
  • Hospital Álvaro Cunqueiro
    Vigo (Pontevedra), 36312, Spain
  • Royal Bournemouth and Christchurch Hospital
    Bournemouth, BH7 7DW, United Kingdom
  • Royal Sussex County Hospital
    Brighton, BN2 5BE, United Kingdom
  • Papworth Hospital
    Cambridge, CB23 3RE, United Kingdom
  • Golden Jubilee National Hospital, Clydebank
    Clydebank, G81 4DY, United Kingdom
  • Castle Hill Hopsital
    Cottingham, HU16 5JQ, United Kingdom
  • Leeds General Infirmary
    Leeds, LS1 3EX, United Kingdom
  • St Bartholomew's Hospital
    London, EC1A 4NP, United Kingdom
  • James Cook University Hospital
    Middlesbrough, TS4 3BW, United Kingdom
  • John Radcliffe Hospital
    Oxford, OX3 9DU, United Kingdom
09

References and documents

Publications

  • Kimata A, Nogami A, Yamasaki H, Ohigashi T, Gosho M, Igarashi M, Sekiguchi Y, Ieda M, Calkins H, Aonuma K. Optimal interruption time of dabigatran oral administration to ablation (O-A time) in patients with atrial fibrillation: Integrated analysis of 2 randomized controlled clinical trials. J Cardiol. 2021 Jun;77(6):652-659. doi: 10.1016/j.jjcc.2020.12.010. Epub 2021 Jan 25. PubMed 33509678 ↗
  • Hohnloser SH, Calkins H, Willems S, Verma A, Schilling R, Okumura K, Nordaby M, Kleine E, Biss B, Gerstenfeld EP; RE-CIRCUIT(R) investigators. Regional differences in patient characteristics and outcomes during uninterrupted anticoagulation with dabigatran versus warfarin in catheter ablation of atrial fibrillation: the RE-CIRCUIT study. J Interv Card Electrophysiol. 2019 Aug;55(2):145-152. doi: 10.1007/s10840-019-00518-x. Epub 2019 Feb 13. PubMed 30758702 ↗
  • Calkins H, Willems S, Gerstenfeld EP, Verma A, Schilling R, Hohnloser SH, Okumura K, Serota H, Nordaby M, Guiver K, Biss B, Brouwer MA, Grimaldi M; RE-CIRCUIT Investigators. Uninterrupted Dabigatran versus Warfarin for Ablation in Atrial Fibrillation. N Engl J Med. 2017 Apr 27;376(17):1627-1636. doi: 10.1056/NEJMoa1701005. Epub 2017 Mar 19. PubMed 28317415 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2015 to primary completion in Nov 2016, 18 months.

Results were first posted in Nov 2017, 1 year after primary completion.

Of 141 phase 4 interventional studies under Atrial Fibrillation, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 81. This study's 18 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 27, 2015
First posted
Jan 28, 2015
StartActual
Apr 28, 2015
Primary completionActual
Nov 11, 2016
CompletionActual
Nov 14, 2016
Results first posted
Nov 14, 2017
Last update
Jan 29, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 29, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02348723
Responsible party
Sponsor
First posted
Jan 28, 2015
Start date
Apr 28, 2015
Primary completion
Nov 11, 2016
Completion
Nov 14, 2016
Results posted
Nov 14, 2017
Last update
Jan 29, 2018

Study contacts

Boehringer Ingelheim
study chair · Boehringer Ingelheim
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dabigatran

Start the discussion